Login / Signup

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.

Kazuhiko NakagawaEdward B GaronLing GaoSophie CalliesAnnamaria ZimmermannRichard WalgrenCarla Visseren-GrulMartin Reck
Published in: Cancer chemotherapy and pharmacology (2022)
ClinicalTrials.gov, NCT02411448.
Keyphrases
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • small cell lung cancer
  • tyrosine kinase
  • squamous cell carcinoma
  • double blind
  • wild type
  • open label